ArticleJournal of inflammation research2025
The Role of EZH2 in Initiating Epigenetic Regulation of CRSwNP.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) was a polygenic disease whose pathogenesis involved epigenetic mechanisms. This study aimed to analyze biomarkers and pathways associated with CRSwNP using RNA-sequencing and explore the role of key biomarkers in the inflammatory response through epigenetic regulation in nasal mucosal cells. Particularly on EZH2, a key epigenetic regulator and histone methyltransferase, to explore its potential for CRSwNP immunotherapy. Patients and Methods: A total of 86 individuals were included between July 2021 and July 2023, including 43 patients with CRSwNP who underwent nasal polyp surgery and 43 patients with a deviated septum. Initially, differentially expressed genes (DEGs) between CRSwNP and control groups were screened using the obtained transcriptomic sequencing CRSwNP dataset. Biomarkers were filtered using machine learning algorithms and validated using immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The expression of enhancer of zeste homolog 2 (EZH2) was knocked down via siRNA and overexpressed through plasmid transfection in human nasal epithelial cells (HNEpCs). The effects of EZH2 overexpression and knockdown on the expression of high-mobility gene group A2 (HMGA2) activation and H3k27me3 expression were assessed using qRT-PCR and immunofluorescence. Results: EZH2, insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), and HMGA2 were revealed as potential biomarkers which screened from five target genes. Gene set enrichment analysis and immune infiltration analysis revealed the most critical gene was EZH2, with its expression exhibiting a positive relationship with HMGA2. Moreover, EZH2 knockdown upregulated H3k27me3 expression and inhibited HMGA2 activation. In contrast, EZH2 overexpression downregulated H3k27me3 expression and promoted HMGA2 activation. Notably, the expression levels of IGF2BP1, EZH2, and HMGA2 were higher in the CRSwNP group than in the control group. Conclusion: This study identified three potential biomarkers, IGF2BP1, EZH2, and HMGA2, associated with CRSwNP. Notably, EZH2 could serve as a new adjuvant immunotherapy target in CRSwNP through the modulation of epigenetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.